Meeting News CoverageVideo

Video: NIAID Ebola vaccine well tolerated, immunogenic

WILMINGTON, Del. — Julie Ledgerwood, DO, of the National Institute of Allergy and Infectious Diseases' Vaccine Research Center, reviews progress on development of the cAd3-EBO vaccine, presented today at the New Technologies, New Vaccines 2015 conference.

Ledgerwood said that the recombinant vaccine, which was rapidly advanced into Phase 1 clinical evaluation, was well tolerated and demonstrated immunogenicity.

Disclosure: Ledgerwood reports no relevant financial disclosures.

WILMINGTON, Del. — Julie Ledgerwood, DO, of the National Institute of Allergy and Infectious Diseases' Vaccine Research Center, reviews progress on development of the cAd3-EBO vaccine, presented today at the New Technologies, New Vaccines 2015 conference.

Ledgerwood said that the recombinant vaccine, which was rapidly advanced into Phase 1 clinical evaluation, was well tolerated and demonstrated immunogenicity.

Disclosure: Ledgerwood reports no relevant financial disclosures.

    See more from Ebola Resource Center